Which of the following is an acceptable response when monitoring a client's response to DMARDs?

Monitoring a client's response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) is essential for managing conditions like rheumatoid arthritis. DMARDs are used to slow disease progression and improve symptoms, making it crucial to evaluate how effectively the medication is working for the patient.

An acceptable response when assessing a client's reaction to DMARD therapy includes symptom control during emotional stress. This indicates that the medication is assisting in managing not just the physical symptoms, but also the psychosocial aspects of the disease. When a patient can maintain symptom control during periods of heightened emotional stress, it suggests that the DMARD is effectively working to stabilize the inflammation and joint pain associated with the underlying condition.

In contrast, aspects like elevated white blood cell counts, progression of joint degeneration on radiology, and severe joint inflammation indicate issues rather than positive responses to treatment. Elevated white blood cell counts often suggest an active inflammatory process or infection, which can be counterproductive to the intended effects of DMARDs. Progression of joint degeneration observed in imaging suggests that the treatment may not be effective in halting the disease's progression. Lastly, severe joint inflammation highlights that the treatment is not adequately controlling the inflammation, which is contrary to the goals of DMARD therapy.

Therefore, symptom control